This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Consistently low MIC values – a potent addition to the treatment options for CAP1,2
In Vitro Susceptibility: MIC Break Points Established by the CLSI for ZINFORO®2,3,*
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
In vitro activity does not always correlate with clinical efficacy.
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae. Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ceftaroline in vitro.2
†The break point for susceptibility is based on a dosage regimen of ceftaroline 600 mg administered q12h.3
‡Available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ceftaroline: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.2
CAP, community-acquired pneumonia; CLSI, Clinical and Laboratory Standards Institute; cSSTI, complicated skin and soft tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin-non–susceptible Streptococcus pneumoniae; q12h, every 12 hours.
References:
Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ZFO-IND-0417 June 2022
Fifth-generation cephalosporin with broad coverage
Simple dosing with a flexible infusion time
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.